ASH 2021 | Advancements in the DLBCL treatment landscape
Peter M. Riedell, MD, University of Chicago Medicine, Chicago, IL, provides an overview of novel diffuse large B-cell lymphoma (DLBCL) therapies. Chimeric antigen receptor (CAR) T-cell therapies and other immunotherapies such as tafasitamab with lenalidomide, as well as loncastuximab teserine, an antibody-drug conjugate, represent promising additions to the current treatment landscape. Dr Riedell additionally highlights potential combinations including bendamustine, rituximab, polatuzumab vedotin. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Transcript (edited for clarity)
In the past 18 months, we’ve had now several new approved therapies in diffuse large B-cell lymphoma. Certainly CAR T-cell therapy, and now we have three FDA-approved products. There’s now tafasitamab in combination with lenalidomide, loncastuximab tesirine and along with bendamustine, rituximab and polatuzumab, are all now active combinations in that space. And that session was really going through some of the data and being able to give some of the treatment providers an understanding of potentially how some of those therapies may fit in the treatment landscape and how we may potentially sequence some of those therapies...
In the past 18 months, we’ve had now several new approved therapies in diffuse large B-cell lymphoma. Certainly CAR T-cell therapy, and now we have three FDA-approved products. There’s now tafasitamab in combination with lenalidomide, loncastuximab tesirine and along with bendamustine, rituximab and polatuzumab, are all now active combinations in that space. And that session was really going through some of the data and being able to give some of the treatment providers an understanding of potentially how some of those therapies may fit in the treatment landscape and how we may potentially sequence some of those therapies.
Read more...
